Navigation Links
Women and men appear to benefit in different ways from AA participation
Date:12/5/2012

n maintaining sobriety, whether or not they were attending AA meetings, and completed specialized assessments of factors like their confidence in their ability to stay sober in particular situations and whether or not their social contacts supported or discouraged efforts to maintain abstinence.

In September 2011, Kelly, Hoeppner and colleagues reported in the journal Addiction that increased confidence in the ability to maintain abstinence in social situations and spending more time with people who supported abstinence were the behavioral changes most strongly associated with successful recovery among overall Project MATCH participants attending AA meetings. The current study reanalyzed some of the data used in the Addiction study to see if there were differences between men and women in the impact of factors included in the assessments.

For both men and women, participation in AA increased confidence in the ability to cope with high-risk drinking situations and increased the number of social contacts who supported recovery efforts. But the effect of both of those changes on the ability to abstain from drinking was about twice as strong for men as for women. In contrast, women benefitted much more than men from improved confidence in their ability to abstain during times when they were sad or depressed. "It is striking that this effect was virtually absent in men while it was a major contributor to women's ability to remain abstinent and to limit the number of drinks they consumed when they did drink," says Hoeppner. Several factors that helped to reduce the intensity of drinking in men such as less depression and fewer friends who encouraged drinking did not appear to be as important for helping women.

Kelly says,"AA helps both men and women stay sober following treatment by enhancing sober social networks and boosting confidence in coping with high-risk social situations. In terms of alcoholism recovery more generally, we fo
'/>"/>

Contact: Kristen Stanton
kstanton3@partners.org
617-643-3907
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. US Drug Watchdog Now Urges Transvaginal Mesh, Tape Or Sling Failure Victims To Call Them For The Names Of The Best Possible Attorneys-Who Are All Also Women-Get Help Now
2. Crittenton Hospital Medical Center in Rochester, MI Welcomes Two Certified Nurse Midwives (CNMs) from Women's Excellence in Midwifery
3. Predictors of postpartum pelvic joint pain identified among working women
4. The US Drug Watchdog Now Urges Women Who Suffered A Heart Attack Or Stroke After Using Yaz Yasmin Birth Control Pills To Contact The Johnson Law Group Immediately
5. US Drug Watchdog Now Fears the Numbers of Transvaginal Mesh Product Failure Victims Will Grow and They Offer Victims the Names of the Best Lawyers-Who Will All Be Women
6. Women 16-49 at risk of multiple pollutants
7. Babies born to mothers from the Philippines significantly smaller than those of Canadian-born women
8. Anthropological expertise facilitates multicultural womens health care
9. Most Women Who Choose Double Mastectomy Dont Need To, Study Shows
10. Most women who have double mastectomy dont need it, U-M study finds
11. Women With Dense Breasts Open to Additional Cancer Screening: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... The results of a 40+ year study ... potential to cause mesothelioma, regardless of the volume of ... the Surviving Mesothelioma website. , The study conducted ... Poland found that, among the 138 cases of mesothelioma ... all of them happened at plants that had, at ...
(Date:5/30/2015)... San Diego, CA (PRWEB) May 30, 2015 ... public is the lack of local healthcare options available. ... access to adequate healthcare. For those in rural areas ... those simply without health insurance or tired of paying ... announces new E-consults, connecting patients with licensed physicians via ...
(Date:5/30/2015)... 30, 2015 On Thursday, May ... Charles Simone and Dr. Evan Alley both of ... the Mesothelioma Experts’ series. The interview was part ... centers of excellence. Drs. Simone and Alley were ... Hesdorffer, with whom they discussed the mesothelioma program ...
(Date:5/30/2015)... May 30, 2015 Boston Scientific ... in punitive and compensatory damages to a transvaginal ... serious complications following implantation of the company’s Pinnacle ... rendered on May 28th in Delaware Superior Court, ... damages after the jury found that the implants ...
(Date:5/30/2015)... ProIntro Magnify contains 30 self-animating and minimalistic Titles including ... elegant opening title to any Final Cut Pro X ... layouts. ProIntro Magnify is created exclusively for Final Cut Pro ... Simply drag a preset into the FCPX timeline ... Inspector window then watch as ProIntro Magnify does the rest. ...
Breaking Medicine News(10 mins):Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2
... Blue Plans in Oregon and Washington ... from HealthLeaders-InterStudy, NASHVILLE, Tenn., July 29 ... reports that Regence,BlueCross BlueShield of Oregon and Regence ... significant play in the Medicare market.,According to the ...
... For International Licensing, LAS VEGAS, July ... http://www.skinvisible.com, , http://www.invisicare.com ), the developers of ... topical skincare products, announces,the successful development of ... ingredient avobenzone (Parsol(R) 1789) with Invisicare. Avobenzone,is ...
... July 29 Studies show that regular,monitoring of ... improve a,patient,s quality of health. Thanks to recent ... all sorts of information about their,patients that they ... with reports that show how regularly,their chronically ill ...
... team of scientists has identified processes that are heavily implicated ... us closer to developing quick tests and readouts that could ... the white blood cells that produce antibodies, form a key ... to maintain the right number of B cells, not too ...
... could quadruple in certain populations if people with HIV ... the Swiss Federal Commission for HIV/AIDS, University of New ... from UNSW,s National Centre in HIV Epidemiology and Clinical ... experts from the Swiss Federal Commission for HIV/AIDS that ...
... spouse quits , , TUESDAY, July 29 (HealthDay News) -- Nonsmokers ... for experiencing a stroke, a new study suggests. , Researchers ... still smoke carry an even greater risk for stroke. However, ... any higher risk for stroke than those married to someone ...
Cached Medicine News:Health News:Regence Group's Oregon and Washington Blue Plans Are Well Positioned for Success in Local Medicare Market 2Health News:Skinvisible Offers 8 Hour Photostablity for Parsol 1789 2Health News:Skinvisible Offers 8 Hour Photostablity for Parsol 1789 3Health News:Highmark's SMART(TM) Registry Reports Aid the Chronically Ill 2Health News:Highmark's SMART(TM) Registry Reports Aid the Chronically Ill 3Health News:How molecules out of balance lead to human multiple myeloma and other cancers 2Health News:A dangerous precedent in HIV 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 3
(Date:5/30/2015)... N.J. , May 30, 2015  Eisai Inc. announced ... which showed that eribulin met the study,s primary endpoint evaluating ... adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma. ... Annual Meeting of the American Society of Clinical Oncology (ASCO) ... ASCO press conference on Saturday, May 30, and also in ...
(Date:5/30/2015)... IRVING, Tex. , May 30, 2015 /PRNewswire/ ... focused on fulfilling the promise of precision medicine, ... studies that demonstrate the utility of Caris Molecular ... in facilitating comparisons between tumors that share histological ... of the American Society of Clinical Oncology (ASCO) ...
(Date:5/29/2015)... OTTAWA , May 29, 2015 /CNW/ - Alliance ... Canada, is recalling the health product Galenic Health ... levels of lead for adolescents and children. The ... limits for children, but within acceptable limits for ... used to relieve digestive upset and disturbances. Alliance ...
Breaking Medicine Technology:Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 2Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 3Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 4Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 5Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 6
... POTTERS BAR, England, Oct. 25, 2011 Mylan Inc. (Nasdaq: ... has launched Rivastigmine Capsules POM, 1.5 mg, 3 mg, 4.5 ... of Novartis, Exelon ® Capsules, a treatment for dementia ... to launch a generic Rivastigmine formulation in the U.K. ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Market to 2017 - Multiple Sclerosis, ... for Half the Market Value in ...
Cached Medicine Technology:Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 2Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 3Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 4Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 5Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 6Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 7Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 8Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 9Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 10Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 11Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 12Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 13Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 14Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 15Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 16Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 17Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 18Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 19Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 20
Colloidal Gold Conjugated, Rabbit anti-goat IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Goat anti-human IgG (H&L) - 12 OD...
Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 12 OD...
Medicine Products: